| 货号 | 12084-5mg |
| 描述 | CI-994 is an inhibitor of class I HDACs displaying IC50 values of 0.9, 0.9, 1.2, and >20 μM when screened in vitro against recombinant human HDAC 1, 2, 3, and 8, respectively.1 CI-994 has a wide spectrum of antitumor activity, particularly in tumors normally refractory to conventional anticancer agents, in preclinical models both in vitroandin vivo and has advanced through phase I and II clinical trials in combination therapy treatments.2,3,4 |
| 别名 | N-Acetyldinaline;Goe 5549;PD 123654;Tacedinaline; |
| 供应商 | Cayman |
| 应用文献 | |
| 1.Moradei, O.M.,Mallais, T.C.,Frechette, S., et al. Novel aminophenyl benzamide-type histone deacetylase inhibitors with enhanced potency and selectivity. Journal of Medicinal Chemistry 50, 5543-5546 (2007). 2.Undevia, S.D.,Kindler, H.L.,Janisch, L., et al. A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine. Annals of Oncology 15(11), 1705-1711 (2004). 3.El-Beltagi, H.M.,Martens, A.C.M.,Lelieveld, P., et al. Acetyldinaline: A new oral cytostatic drug with impressive differential activity against leukemic cells and normal stem cells--preclinical studies in a relevant rat model for human acute myelocytic leukemia. Cancer Research 53, 3008-3014 (1993). 4.Perabo, F.G.E., and Müller, S.C. New agents for treatment of advanced transitional cell carcinoma. Annals of Oncology 18, 835-843 (2007). | |
| 运输条件 | Room temperature in continental US; may vary elsewhere |
| 存放说明 | -20 |
| 纯度 | ≥98% |
| 计算分子量 | 269.3 |
| 分子式 | C15H15N3O2 |
| CAS号 | 112522-64-2 |
| 稳定性 | ≥ 2 years |
| 本官网所有报价均为常温或者蓝冰运输价格，如有产品需要干冰运输，需另外加收干冰运输费。 |